How to remember biological therapeuticsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3010 (Published 18 May 2012) Cite this as: BMJ 2012;344:e3010
- Neil Samuel Nyholm Graham, foundation year 1 doctor, Guy’s and St Thomas’ NHS Foundation Trust, London
Some will be aware that the ever expanding repertoire of monoclonal antibody drugs benefits from systematic naming rules, but for those who are not, there is hope: we can understand the non-proprietary names of these drugs, even if we can’t afford to give them to our patients.
Drug names such as “infliximab” are built of four components: [unique naming part] + [target] + [type] + [“mab”].1
Let’s start at the end. What is it? A monoclonal …